Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Gemcitabine With Vaccine Therapy Targeting Tumor Antigen, URLC10, For The Patients With Unresectable or Recurrent Bile Duct Cancer

NCT00624182 is registered in ClinicalTrials.gov with Akita University Hospital as lead sponsor.

NCT NCT00624182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00624182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Gemcitabine With Vaccine Therapy Targeting Tumor Antigen, URLC10, For The Patients With Unresectable or Recurrent Bile Duct Cancer
Lead sponsor
Akita University Hospital
Phase
Phase 1
Overall status
Suspended
Start date
February 29, 2008
Completion date
December 31, 2016
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bile duct cancer